• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 12,034 shares, decreasing direct ownership by 4% to 295,282 units (SEC Form 4)

    6/26/25 4:48:44 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Maersk-Moller Kimberly

    (Last) (First) (Middle)
    1775 WEST OAK COMMONS COURT

    (Street)
    MARIETTA GA 30062

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MIMEDX GROUP, INC. [ MDXG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Commercial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    06/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/24/2025 F 12,034(1) D $5.96 295,282 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld for payment of tax liability upon vesting of restricted stock units.
    Remarks:
    /s/ William F. Hulse, as attorney-in-fact for Kimberly Maersk-Moller 06/26/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MDXG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      11/22/23 5:01:18 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

      Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

      7/30/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

      MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Vaporox, Inc. ("Vaporox") today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy ("VHT") device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a

      7/30/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

      MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website

      7/16/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

      Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

      7/2/24 7:38:13 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on MiMedx Group with a new price target

      Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

      3/7/24 8:26:30 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on MiMedx Group with a new price target

      Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

      10/27/23 9:04:53 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    SEC Filings

    See more
    • MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

      7/30/25 4:03:53 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MiMedx Group Inc

      10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)

      7/30/25 4:01:02 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by MiMedx Group Inc

      S-8 - MIMEDX GROUP, INC. (0001376339) (Filer)

      7/28/25 4:25:39 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 6% to 188,024 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      7/7/25 5:59:59 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 12,034 shares, decreasing direct ownership by 4% to 295,282 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      6/26/25 4:48:44 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Newton Todd was granted 28,609 shares, increasing direct ownership by 7% to 412,771 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      6/23/25 6:46:57 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Financials

    Live finance-specific insights

    See more
    • MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

      Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

      7/30/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

      MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website

      7/16/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces First Quarter 2025 Operating and Financial Results

      Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total

      4/30/25 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

      SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/12/24 4:04:33 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MiMedx Group Inc

      SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/7/24 10:25:58 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

      SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

      11/4/24 1:30:50 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    See more
    • Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

      Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

      7/17/24 8:00:00 AM ET
      $MDXG
      $SAVA
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

      MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

      6/26/24 4:01:00 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces Appointment of Two New Independent Directors

      MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

      3/4/24 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care